<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04302428</url>
  </required_header>
  <id_info>
    <org_study_id>1907847033</org_study_id>
    <nct_id>NCT04302428</nct_id>
  </id_info>
  <brief_title>Zinc Status and Growth in Cystic Fibrosis</brief_title>
  <official_title>Zinc Status and Growth in Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indiana University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indiana University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to improve the understanding of the relationship of zinc status
      and growth in infants and young children who were diagnosed with cystic fibrosis via newborn
      screening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this study is to improve the understanding of the relationship of zinc (Zn)
      status and growth in infant and young people with cystic fibrosis (PWCF). The investigators
      hypothesize that Zn deficiency in infant and young PWCF is associated with poor growth.

      Aim #2: To study the association between Zn levels in red blood cells and nutritional status
      in PWCF at 3 months to 3 years of age and compare it to the association between serum Zn and
      nutritional status in the same population. Hypothesis: Lower Zn levels in red blood cells is
      associated with poorer nutritional status in infant and young PWCF and is a better measure of
      Zn status compared to serum Zn.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 29, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Zinc Status</measure>
    <time_frame>1 day</time_frame>
    <description>Zn status in infant and young PWCF as measured by serum Zn and red blood cell Zn</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Cystic</condition>
  <condition>Fibrosis</condition>
  <arm_group>
    <arm_group_label>Pediatric CF Patients</arm_group_label>
    <description>Pediatric patients ages 3 months to 3 years with CF identified via newborn screening.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Serum Zn</intervention_name>
    <description>The investigators will obtain an additional 2 mL of blood in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.</description>
    <arm_group_label>Pediatric CF Patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Red Blood Cell Zn</intervention_name>
    <description>If the participant is greater or equal than 5 kg, an additional 2 mL of blood will be obtained in an extra tube. This will be collected at the same time blood is collected for the participant's yearly CF screening labs so as to minimize additional needle sticks.</description>
    <arm_group_label>Pediatric CF Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Pediatric patients ages 3 months to 3 years with CF identified via new born screening
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pediatric patients ages 3 months to 3 years with CF identified via new born screening

        Exclusion Criteria:

          -  History of meconium ileus

          -  History of prematurity (born prior to completing 36 weeks 6 days gestation)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clement Ren, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Indiana University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sarah Bauer, MD</last_name>
    <phone>317-948-7208</phone>
    <email>bauersae@iu.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Riley Hospital for Children at Indiana University Health</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Bauer, MD</last_name>
      <phone>317-948-7208</phone>
      <email>bauersae@iu.edu</email>
    </contact>
    <investigator>
      <last_name>Clement Ren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 6, 2020</study_first_submitted>
  <study_first_submitted_qc>March 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 10, 2020</study_first_posted>
  <last_update_submitted>March 14, 2020</last_update_submitted>
  <last_update_submitted_qc>March 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indiana University</investigator_affiliation>
    <investigator_full_name>Clement L. Ren, MD, MBA</investigator_full_name>
    <investigator_title>Director, Cystic Fibrosis Center &amp; Professor, School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Zinc</keyword>
  <keyword>Growth</keyword>
  <keyword>Nutrition</keyword>
  <keyword>Cystic</keyword>
  <keyword>Fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

